Xencor Inc
XNCR15.450USD
-0.020-0.13%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.10BMarket Cap
LossP/E TTM
More Details of Xencor Inc Company
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Xencor Inc Info
Ticker SymbolXNCR
Company nameXencor Inc
IPO dateDec 03, 2013
CEODahiyat (Bassil I)
Number of employees250
Security typeOrdinary Share
Fiscal year-endDec 03
Address465 N. Halstead St.
CityPASADENA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code91107
Phone16263055900
Websitehttps://xencor.com/
Ticker SymbolXNCR
IPO dateDec 03, 2013
CEODahiyat (Bassil I)
Company Executives of Xencor Inc
Name
Name/Position
Position
Shareholding
Change
Dr. John R. Desjarlais, Ph.D.
Dr. John R. Desjarlais, Ph.D.
Executive Vice President - Research, Chief Scientific Officer
Executive Vice President - Research, Chief Scientific Officer
212.96K
+10.45%
Ms. Celia E. Eckert
Ms. Celia E. Eckert
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
50.68K
+47.02%
Mr. Bart Jan Cornelissen
Mr. Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
Senior Vice President, Chief Financial Officer
33.17K
-10.16%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Independent Director
Independent Director
14.20K
+305.17%
Mr. Todd E. Simpson
Mr. Todd E. Simpson
Independent Director
Independent Director
13.69K
--
Mr. Richard J. (Rich) Ranieri
Mr. Richard J. (Rich) Ranieri
Independent Director
Independent Director
13.20K
+427.04%
Dr. Kevin C. Gorman, Ph.D.
Dr. Kevin C. Gorman, Ph.D.
Independent Director
Independent Director
--
--
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
President, Chief Executive Officer, Founder and Director
President, Chief Executive Officer, Founder and Director
--
--
Dr. A. Bruce Montgomery, M.D.
Dr. A. Bruce Montgomery, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Ellen Gwen Feigal, M.D.
Dr. Ellen Gwen Feigal, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. John R. Desjarlais, Ph.D.
Dr. John R. Desjarlais, Ph.D.
Executive Vice President - Research, Chief Scientific Officer
Executive Vice President - Research, Chief Scientific Officer
212.96K
+10.45%
Ms. Celia E. Eckert
Ms. Celia E. Eckert
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
50.68K
+47.02%
Mr. Bart Jan Cornelissen
Mr. Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
Senior Vice President, Chief Financial Officer
33.17K
-10.16%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Independent Director
Independent Director
14.20K
+305.17%
Mr. Todd E. Simpson
Mr. Todd E. Simpson
Independent Director
Independent Director
13.69K
--
Mr. Richard J. (Rich) Ranieri
Mr. Richard J. (Rich) Ranieri
Independent Director
Independent Director
13.20K
+427.04%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Milestone
25.00M
57.33%
Royalties
18.61M
42.67%
Licensing
0.00
0.00%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Milestone
25.00M
57.33%
Royalties
18.61M
42.67%
Licensing
0.00
0.00%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
PRIMECAP Management Company
14.95%
BlackRock Institutional Trust Company, N.A.
14.82%
The Vanguard Group, Inc.
10.04%
RTW Investments L.P.
8.71%
EcoR1 Capital, LLC
8.60%
Other
42.88%
Shareholders
Shareholders
Proportion
PRIMECAP Management Company
14.95%
BlackRock Institutional Trust Company, N.A.
14.82%
The Vanguard Group, Inc.
10.04%
RTW Investments L.P.
8.71%
EcoR1 Capital, LLC
8.60%
Other
42.88%
Shareholder Types
Shareholders
Proportion
Investment Advisor
57.50%
Investment Advisor/Hedge Fund
36.52%
Hedge Fund
18.65%
Research Firm
3.84%
Individual Investor
1.31%
Venture Capital
1.05%
Pension Fund
0.92%
Bank and Trust
0.37%
Sovereign Wealth Fund
0.08%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
434
80.43M
112.65%
-6.04M
2025Q2
437
81.68M
114.52%
-1.81M
2025Q1
459
80.70M
113.40%
-3.00M
2024Q4
454
76.54M
108.64%
-2.55M
2024Q3
455
73.66M
105.55%
+3.66M
2024Q2
436
65.64M
106.20%
-4.06M
2024Q1
431
66.91M
108.52%
-498.74K
2023Q4
420
65.39M
107.20%
-1.62M
2023Q3
417
65.14M
107.37%
-1.33M
2023Q2
422
64.91M
107.12%
-2.55M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
PRIMECAP Management Company
10.53M
14.76%
+766.31K
+7.85%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
10.67M
14.97%
-68.43K
-0.64%
Jun 30, 2025
The Vanguard Group, Inc.
8.61M
12.07%
+725.91K
+9.21%
Jun 30, 2025
RTW Investments L.P.
2.40M
3.37%
--
--
Jun 30, 2025
EcoR1 Capital, LLC
6.14M
8.62%
--
--
Jun 30, 2025
BVF Partners L.P.
2.74M
3.84%
--
--
Jun 30, 2025
State Street Investment Management (US)
3.82M
5.35%
+133.90K
+3.63%
Jun 30, 2025
TCG Crossover Management, LLC
2.45M
3.44%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
1.70M
2.39%
+29.32K
+1.75%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
1.78M
2.5%
+43.18K
+2.49%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
2.09%
Tema Oncology ETF
1.16%
Virtus LifeSci Biotech Clinical Trials ETF
1.06%
Invesco NASDAQ Future Gen 200 ETF
0.97%
Invesco S&P SmallCap Health Care ETF
0.64%
ALPS Medical Breakthroughs ETF
0.43%
State Street SPDR S&P Biotech ETF
0.33%
Inspire Small/Mid Cap ESG ETF
0.3%
Direxion Daily S&P Biotech Bull 3X Shares
0.15%
ProShares Ultra Nasdaq Biotechnology
0.15%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion2.09%
Tema Oncology ETF
Proportion1.16%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.06%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.97%
Invesco S&P SmallCap Health Care ETF
Proportion0.64%
ALPS Medical Breakthroughs ETF
Proportion0.43%
State Street SPDR S&P Biotech ETF
Proportion0.33%
Inspire Small/Mid Cap ESG ETF
Proportion0.3%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.15%
ProShares Ultra Nasdaq Biotechnology
Proportion0.15%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Xencor Inc?
The top five shareholders of Xencor Inc are:
PRIMECAP Management Company holds 10.53M shares, accounting for 14.76% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 10.67M shares, accounting for 14.97% of the total shares.
The Vanguard Group, Inc. holds 8.61M shares, accounting for 12.07% of the total shares.
RTW Investments L.P. holds 2.40M shares, accounting for 3.37% of the total shares.
EcoR1 Capital, LLC holds 6.14M shares, accounting for 8.62% of the total shares.
PRIMECAP Management Company holds 10.53M shares, accounting for 14.76% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 10.67M shares, accounting for 14.97% of the total shares.
The Vanguard Group, Inc. holds 8.61M shares, accounting for 12.07% of the total shares.
RTW Investments L.P. holds 2.40M shares, accounting for 3.37% of the total shares.
EcoR1 Capital, LLC holds 6.14M shares, accounting for 8.62% of the total shares.
What are the top three shareholder types of Xencor Inc?
The top three shareholder types of Xencor Inc are:
PRIMECAP Management Company
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
PRIMECAP Management Company
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
How many institutions hold shares of Xencor Inc (XNCR)?
As of 2025Q3, 434 institutions hold shares of Xencor Inc, with a combined market value of approximately 80.43M, accounting for 112.65% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -1.87%.
What is the biggest source of revenue for Xencor Inc?
In FY2025Q2, the Milestone business generated the highest revenue for Xencor Inc, amounting to 25.00M and accounting for 57.33% of total revenue.
